Currax Pharmaceuticals to Spotlight New Research at ObesityWeek(R) 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE(R)

BRENTWOOD, Tenn., Oct. 28, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax"), a pharmaceutical, company that delivers life-changing medicines to patients with chronic, progressive diseases, ...
abc27

Currax Pharmaceuticals LLC to Provide CONTRAVE® at No Cost to Federal Employees During Government Shutdown

Program ensures continued access to treatment for patients enrolled in the Federal Employee & Retirees Health Plan (FEP) BRENTWOOD, Tenn., Oct. 23, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC, a ...

Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes …

Data to be shared during an ObesityWeek press conference includes four of seven data presentations supporting CONTRAVE and ...